XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue
 3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended March 31,
 20212020
Net product revenue$6,320.0 $5,403.5 
Collaboration and other revenue (1)
485.6 456.3 
Revenue$6,805.6 $5,859.8 
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $43.0 million and $35.4 million during the three months ended March 31, 2021 and 2020, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance® and Trajenta® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Adjustments to Revenue
Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 2 percent of U.S. revenue during the three months ended March 31, 2021 and 2020.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
The following table summarizes contract liability balances:
 March 31, 2021December 31, 2020
Contract liabilities$346.6 $276.8 
During the three months ended March 31, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.
Disaggregation of Revenue
The following table summarizes revenue by product for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
 20212020
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®
$1,116.8 $335.7 $1,452.4 $929.5 $299.9 $1,229.4 
Humalog® (1)
332.7 284.4 617.0 398.6 297.2 695.8 
Humulin®
219.0 102.7 321.7 214.1 101.5 315.7 
Jardiance (2)
151.2 160.8 312.0 144.6 122.9 267.5 
Basaglar®
175.2 71.4 246.6 230.4 73.3 303.7 
Other Diabetes66.3 94.9 161.4 74.0 82.9 156.8 
Total Diabetes2,061.2 1,049.9 3,111.1 1,991.2 977.7 2,968.9 
Oncology:
Alimta®
261.1 297.8 559.0 324.2 235.8 560.1 
Verzenio®
172.8 96.2 269.0 129.4 58.6 188.0 
Cyramza®
80.2 160.3 240.5 89.1 149.9 239.0 
Erbitux®
107.9 14.4 122.4 117.8 13.0 130.8 
Tyvyt®
— 109.7 109.7 — 57.4 57.4 
Other Oncology20.5 51.3 71.6 (2.6)28.9 26.2 
Total Oncology642.5 729.7 1,372.2 657.9 543.6 1,201.5 
Immunology:
Taltz®
249.6 153.6 403.2 327.5 116.0 443.5 
Olumiant®
24.7 169.1 193.8 11.3 128.4 139.7 
Other Immunology10.5 6.4 16.9 2.6 — 2.6 
Total Immunology284.8 329.1 613.9 341.4 244.4 585.8 
Neuroscience:
Cymbalta®
11.0 165.7 176.6 11.6 198.8 210.4 
Emgality®
101.5 18.0 119.5 67.3 6.7 74.0 
Zyprexa®
6.9 88.9 95.8 11.2 87.2 98.4 
Other Neuroscience22.3 51.1 73.5 20.2 60.5 80.7 
Total Neuroscience141.7 323.7 465.4 110.3 353.2 463.5 
Other:
COVID-19 Antibodies (3)
650.6 159.5 810.1 — — — 
Forteo®
97.7 100.8 198.5 122.5 149.8 272.4 
Cialis®
8.6 118.1 126.8 26.1 167.0 193.0 
Other54.2 53.4 107.5 79.4 95.3 174.7 
Total Other811.1 431.8 1,242.9 228.0 412.1 640.1 
Revenue$3,941.3 $2,864.3 $6,805.6 $3,328.8 $2,531.0 $5,859.8 
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(3) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs).
The following table summarizes revenue by geographical area:
Three Months Ended March 31,
20212020
Revenue—to unaffiliated customers (1):
U.S.$3,941.3 $3,328.8 
Europe1,321.2 1,061.0 
Japan571.8 592.3 
China362.2 267.3 
Other foreign countries609.1 610.4 
Revenue$6,805.6 $5,859.8 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.